Marinol and Syndros contain the same active drug, dronabinol, but they are not the same formulation. Marinol is a capsule and Syndros is an oral solution; that difference matters because the labels describe different inactive ingredients, controlled-substance schedules, warnings, and practical monitoring questions. Both are prescription medicines, not over-the-counter products.
The FDA identifies dronabinol as synthetic delta-9 THC, the psychoactive component of cannabis. It approves Marinol and Syndros for certain therapeutic uses, including appetite loss with weight loss in people with AIDS, while the exact product label tells you what applies to the medicine in front of you.
Why does formulation matter with Marinol and Syndros?
Formulation is more than a different package. It is the complete version of a medicine: the active agent, its physical form, the other ingredients, and the instructions and warnings attached to that specific product.
| Feature | Marinol | Syndros |
|---|---|---|
| Active agent | Dronabinol | Dronabinol |
| Form | Oral capsule | Oral solution |
| Controlled-substance classification | Schedule III, according to Healio | Schedule II, according to the Syndros prescribing information |
| Notable formulation detail | Capsule form; check the Marinol label for inactive ingredients | The label lists 50% dehydrated alcohol and 5.5% propylene glycol |
That last row is a good example of why a class-wide shortcut can cause trouble. The Syndros label lists alcohol sensitivity and recent use of disulfiram- or metronidazole-containing products among its contraindications. Those are formulation-specific issues that deserve a pharmacist’s attention when comparing options.
Can one product label be applied to the other?
No. The shared drug does not make the labels interchangeable. The Syndros label bases its safety information on dronabinol capsule studies in some places, but it also gives specific warnings for its liquid formulation, including the alcohol and propylene glycol it contains. A prescriber and pharmacist should use the exact label for the product prescribed rather than treating “dronabinol” as one uniform product.
This same principle applies to monitoring and coverage. A plan may evaluate the precise National Drug Code, dosage form, diagnosis, prior-treatment history, and its own pharmacy-benefit rules. Bring the prescription details and your current medication list when asking about coverage. For a broader framework on comparing a prescription option with nonprescription approaches, see this prescription decision guide.
What are Marinol and Syndros prescribed for?
According to MedlinePlus, dronabinol is used for nausea and vomiting caused by chemotherapy after other medicines have not worked well, and for loss of appetite and weight loss in people with AIDS. The Syndros label states these indications for adults: anorexia associated with weight loss in patients with AIDS, and chemotherapy-associated nausea and vomiting in people who have not responded adequately to conventional antiemetics.
These are exact labeled uses. They do not make every THC-containing product, cannabis product, or dronabinol formulation equivalent for another condition or situation. The CDC likewise distinguishes FDA-approved synthetic THC medicines from other cannabis products and notes that approved products are available only by prescription.
Does dronabinol make you feel high?
It can. Dronabinol is synthetic THC, and the Syndros label describes reversible effects on appetite, mood, cognition, memory, and perception. Its listed common adverse reactions include dizziness, euphoria, somnolence, abnormal thinking, nausea, vomiting, abdominal pain, and paranoid reaction.
The experience can vary with the formulation, prescribed amount, other medicines, health conditions, and the individual. The National Institute on Drug Abuse explains that THC can change mood, thoughts, and perception, and can impair thinking, memory, and body movement. The Syndros label also warns about psychiatric and cognitive effects and impaired ability to perform hazardous tasks. Discuss changes in mood, thinking, dizziness, fainting, or troublesome nausea with the prescribing team promptly.
What safety and interaction questions should you raise?
Use the medicine-specific label as the starting point. The Syndros label calls attention to psychiatric history, seizure history, cardiac disorders, pregnancy, substance-use history, and other medicines that can add sedation or affect dronabinol exposure. It specifically identifies CYP2C9 and CYP3A4 inhibitors and inducers, as well as highly protein-bound medicines such as warfarin, cyclosporine, and amphotericin B, as items for clinical monitoring.
MedlinePlus advises sharing every prescription medicine, over-the-counter medicine, vitamin, mineral, and dietary supplement with your prescriber and pharmacist before starting, stopping, or changing medicines while taking dronabinol. This is also a useful habit when evaluating supplement safety; this AHCC safety guide shows the kind of label and interaction details worth bringing to a medication conversation.
Does Medicare pay for Marinol or Syndros?
Coverage is not a single yes-or-no answer. Your plan may apply its own formulary, prior authorization, diagnosis, formulation, pharmacy network, and refill rules. Ask the plan whether it covers the exact product and dosage form on the prescription, what authorization is required, what your out-of-pocket cost would be, and whether its preferred product differs from the one prescribed.
Do not assume that coverage of a Marinol capsule means coverage of Syndros solution, or the reverse. The different Schedule III and Schedule II classifications reported for the two products may also matter to dispensing and refill processes. Prices and benefits can change, so confirm them with the plan and dispensing pharmacy before filling a prescription.
Is Megace better than Marinol?
“Better” depends on the exact reason appetite support is being considered, your medical history, other medicines, and the outcome you and the prescriber are trying to address. This comparison cannot be settled by applying the Marinol or Syndros label to another medicine. Ask the prescriber to compare the exact indication, expected monitoring, interaction profile, formulation, and coverage for each named option.
What to compare, track, bring and ask
- Compare: the exact active drug, capsule versus oral solution, inactive ingredients, approved indication, Schedule classification, and pharmacy coverage.
- Track: appetite-related changes, nausea or vomiting, dizziness, sleepiness, mood or thinking changes, and any fainting or rapid-heartbeat symptoms.
- Bring: your medication list, supplements, allergy history, insurance card, and the exact product name on the prescription.
- Ask: which label applies to your prescription, whether your other medicines raise an interaction concern, what monitoring is planned, and what the plan requires for coverage.
The practical next step is to review the options with a qualified prescriber and pharmacist. They can match the exact dronabinol formulation, label, indication, monitoring plan, and coverage rules to your situation.
By the Integrative Health Evidence Guide Team
This article is for general information purposes only and does not constitute medical advice. Consult your doctor or qualified healthcare provider before making changes to your health routine.